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SUMMARY:  
We report a 25% increase in Dolutegravir Cmax in people living with 
HIV≥60yrs compared to younger subjects. Discontinuation rate was 4.6%; 
interestingly, PK parameters were not associated with sleep or cognition 
changes over six months in those who continued DTG. 
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This data was presented in part at the annual Conference on Retroviruses and Opportunistic 
Infections (CROI), 3-6 February 2017, Seattle, USA and at the 18th International Workshop 
on Clinical Pharmacology of Antiviral Therapy, 14-16
th
 June 2017, Chicago, IL, USA 
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ABSTRACT 
Background 
Demographic data show an increasingly aging HIV population worldwide. Recent concerns 
over dolutegravir-related neuropsychiatric toxicity have emerged, particularly amongst older 
HIV patients. We describe the pharmacokinetics (PK) of dolutegravir (DTG) 50mg once daily 
in people living with HIV (PLWH) aged 60 and older. Additionally, to address the call for 
prospective neuropsychiatric toxicodynamic data, we evaluate changes in sleep quality and 
cognitive function after switching to abacavir (ABC)/lamivudine (3TC)/DTG, over 6 months 
in this population. 
Methods 
PLWH aged≥60years with HIV-RNA<50copies/mL on any non-DTG based antiretroviral 
combination were switched to ABC/3TC/DTG. On day 28, 24-hour PK sampling was 
undertaken. Steady-state PK parameters were compared to a published historical control 
population aged≤50years. Six validated sleep questionnaires and neurocognitive (Cogstate®) 
testing were administered pre-switch and over 180 days (NCT02509195). 
Results: Forty-three participants were enrolled; 40 completed the PK phase. Overall, five 
discontinued (two due adverse events, both sleep related, 4.6%). DTG maximum 
concentration (Cmax) was significantly higher in patients≥60 versus controls (GM 4246ng/mL 
versus 3402ng/mL, p=0.005). In those who completed day 180 (n=38), sleep impairment was 
higher at day 28 (PSQI median global score 5.0 versus 6.0 p=0.02) but not at day 90 or 180. 
Insomnia, daytime function, fatigue test scores did not change statistically over time. 
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DTG Cmax was significantly higher in older PLWH. Our data provides clinicians with key 
information on the safety of prescribing DTG in older PLWH. 
 
KEY WORDS: Aging, HIV, Dolutegravir, Pharmacokinetics, Sleep 
  
Conclusion:  
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INTRODUCTION 
By 2015, one in three people accessing HIV care in the UK [1] and almost half in the 
US were aged 50 and over [2]. With advancing age, several physiological changes 
affect drug pharmacokinetics (PK) and pharmacodynamics (PD) [3]. 
The integrase inhibitor (InSTI) dolutegravir (DTG) is now the drug of choice for 
many HIV providers, thanks to high efficacy firmly demonstrated in trials and 
retained activity against some InSTI-resistant HIV-1 phenotypes [4]. Its low potential 
for drug-interactions is also an advantage in managing older people living with HIV 
(PLWH) [5]. DTG is a recommended key drug in major HIV guidelines and is a 
strong candidate to become first option in the WHO antiretroviral guidelines [6, 7]. 
In pre-marketing trials, DTG demonstrated favorable safety and tolerability profiles, 
with a <2% discontinuation rate secondary to any adverse events (AEs), comparable 
to raltegravir and superior to efavirenz [8, 9]. However, contrasting real-life data 
reveal unexpectedly higher rates (7-15%, median time 72 days) [10-14], most 
commonly due to insomnia/sleep disturbances and other neuropsychiatric (NP) AEs 
(up to 8%), regardless of prior neuropsychiatric history, thereby implicating a 
potentially neurotoxic effect of DTG [14-18]. Comparison studies suggest that NP-
AEs are commoner with DTG than other InSTIs [11, 12, 16]. Interestingly, in several 
reports, DTG discontinuation was significantly higher in PLWH>60 years old [13, 16, 
19], a group under-represented in licensing trials. This prompted a call in the literature 
for prospective studies evaluating DTG-associated AEs, including PK, sleep 
architecture analysis and neuropsychological testing, particularly in special 
populations [20]. 
A high prevalence of sleep disturbances is already described in the HIV population, 
even in the cART era, (30-73% versus 10-20% in the general population [21, 22]) and 
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it is strongly associated with poorer disease outcomes, cognitive impairment and 
HIV-associated dementia [21, 23]. 
It is, therefore, important to characterise the role of aging on DTG PK/PD, especially with 
regards to central nervous system (CNS) toxicity and sleep disturbances. The primary 
objectives of this study were to describe the steady state PK of DTG 50 mg once daily (OD) 
in PLWH≥60 years and compare them to a published younger population (from the SINGLE 
trial [9]). The secondary objectives were to evaluate, in detail, changes in sleep and cognition 
over six months following a switch from non-DTG-based cART to abacavir (ABC), 
lamivudine (3TC) and DTG, as a fixed dose combination (FDC) tablet.  
We hypothesised that age-related changes in drug PK might impact DTG, except its 
metabolism since it is mainly by UDP-glucuronosyltransferase-1A1 (UGT1A1) and no 
evidence supports age-related glucuronidation changes [24]. We also expected a reverse-
association between sleep/cognition changes and PK parameters, particularly at the high end 
of the therapeutic range (or higher). 
 
METHODS 
Participants 
Written informed consent was obtained from male and female PLWH, stable on cART, 
aged≥60 years with a body mass index (BMI) 18-35 kg/m2. The protocol required that 
approximately 70% of subjects be ≥65 years (to ensure a variable age range). Eligibility 
criteria included plasma HIV-RNA<50 copies/mL at screening and no history of treatment 
failure or documented significant drug resistance on viral genotyping. With ABC use, a 
negative HLA-B*5701 allele result was required and participants were screened for 
cardiovascular (CV) risk using the QRISK2 calculator [6, 25] (eligible if 10-year risk of CV 
event was <20% or if risk factors were well controlled with medication/lifestyle measures). 
Participants were excluded if they had: significant acute/chronic illnesses; abnormal physical 
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examination, ECG or laboratory determinations or use of known interacting drugs/remedies. 
No patients had preceding Primary Sleep Disorder diagnoses. The study was approved by the 
London Central Research Ethics Committee and the Medicines and Healthcare products 
Regulatory Agency (MHRA) and ran in accordance with Good Clinical Practice and the 
Declaration of Helsinki (NCT02509195). 
Study design 
This was a four-centre, 180-day (excluding screening and follow-up), open-label, prospective 
PK/PD study. After screening, eligible subjects were switched to ABC/3TC/DTG 600/300/50 
mg FDC (Triumeq
®
) on day 1, one pill OD, orally, in the morning with or without breakfast 
for the study period, except on day 28. On D28, subjects underwent intensive DTG PK 
determinations, having fasted for six hours pre-dose and four hours post-dose to match the 
SINGLE PK sub-study circumstances [9]. Blood samples were collected pre-dose, 1, 2, 3, 4, 
8, 12 and 24 hours post-dose. Study medications safety was evaluated using the National 
Institute of Allergy and Infectious Diseases Division of AIDS (NIAID2004). Medication 
compliance was assessed through direct questioning and pill count. 
Collection and quantification of plasma dolutegravir 
Whole blood samples were collected at each time-point on D28, from an indwelling venous 
catheter, into 6 mL spray-coated EDTA tubes, Following centrifugation, plasma was 
aliquoted equally into three 2.0mL tubes (Sarstedt, Germany) and stored at -80
o
C.  Samples 
were then shipped on dry ice to the Jefferiss Trust Laboratory (Imperial College London). 
DTG plasma concentrations were determined using ultra-performance liquid chromatography 
(UPLC) coupled with UV detection [26]. 
The assay calibration range was 0.25-10 mcg/ml, intra-assay variability 3.3%-6.1% and inter-
assay variability 4.5%-5.7%. Overall accuracy was between 90.7% and 97.7% for three 
different quality control sample concentrations. The laboratory adheres to the ARV 
International Inter-laboratory Quality Control Program [27]. 
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Pharmacokinetic and statistical analysis 
A sample size of 40 subjects was calculated to provide at least 80% power to detect DTG PK 
parameter changes in older people against 16 controls. The calculated parameters were 
plasma concentration measured 24 hours after the observed dose (C24), maximum observed 
plasma concentration (Cmax), area-under-the-plasma-concentration-curve from 0 to 24 hours 
(AUC0–24) and half-life (t1/2). All PK parameters were calculated using actual blood sampling 
time and non-compartmental modelling techniques (WinNonlin-Phoenix, version 7.0). 
Descriptive statistics, including geometric mean (GM), 95% confidence interval (CI) and 
percentage coefficient of variation (CV%=100*standard deviation/mean) were calculated for 
DTG PK parameters at all time-points on D28, and compared to those obtained from the 
SINGLE PK sub-study control HIV population (≤50 years, n =16) [9] using non-parametric 
Mann-Whitney U test. 
Sleep and cognitive data collection  
Six published and validated self-reported paper questionnaires (table1) [28-33], recording 
different aspects of sleep, were administered to participants at baseline and on days 28, 90 
and 180 in order to provide a comprehensive description of sleep quantity, quality and impact 
on daytime function, wakefulness, mental status and general wellbeing before and after 
medication switch. Answers to each question were coded as per questionnaire protocols 
(supplementary material) and entered into Excel for scoring.  
Neurocognitive testing was carried out on D1 and D180 using the validated, widely used 
Cogstate® computerised assessment software [34], which evaluates a range of cognitive 
functions through eight domains: detection (DET)/identification (IDN) (speed of 
performance); card learning (OCL), one back memory (OBM)/two back memory (TWOB) 
(accuracy of performance); Groton Maze learning (GML), Groton Maze recall (GMR), and 
set-shifting (SETS) (number of errors made on testing). Participants completed a mock 
practice at screening to minimise learning effect. 
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Sleep and cognitive data analysis  
Sleep baseline characteristics and outcome measures at each time-point were descriptively 
summarised using medians, interquartile ranges (IQR), and proportions. Composite scores for 
sleep questionnaires were calculated and interpreted as per questionnaire protocols and cut-
offs (table 1). Neurocognitive scores were analysed using Cogstate® recommendations [35]. 
Changes in cognitive scores were calculated for each subject for each domain  (baseline-
D180), and were standardised according to the within-subject standard deviation (WSD). The 
score sign was reversed where appropriate so positive values represent improvement for all 
domains. A composite score for the change from baseline was calculated by averaging the 
standardised change scores across all Cogstate® tasks for each individual.  
As data was not normally distributed, non-parametric tests were used for analysis. Changes in 
sleep and cognitive scores from baseline to each time-point were tested for significance using 
the Wilcoxon sign-rank test. Spearman’s correlation examined correlations between outcomes 
and DTG PK parameters. 
As efavirenz use is associated with NP-AEs, especially sleep disturbances [6], a sub-analysis 
was conducted using the Mann-Whitney test to compare individuals who switched from an 
efavirenz-based regimen to those who didn’t, thereby preventing efavirenz removal from 
potentially masking DTG effects. 
Internal consistency was evaluated for outcomes with multiple domains using Cronbach’s α 
and corrected component-total Spearman’s rho (rs) correlationsα (≥.70 and rs ≥.30 indicated 
adequate internal consistency). Correlation between different sleep questionnaires was 
evaluated at baseline to determine the level of agreement.  
Statistical analyses were performed using Stata (version 14.1) and GraphPad Prism (version 
7.03). In the analyses, p-values, uncorrected and corrected for multiple comparisons, were 
calculated; p<0.05 was deemed significant. 
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RESULTS 
Study population 
Fifty-three subjects were screened; 43 enrolled and received at least one study drug dose. 
Three/43 participants withdrew before D28 and could not be included in the PK analysis (two 
moved abroad and one experienced fatigue and photosensitivity attributed to the study drugs). 
Forty participants completed the PK phase and 38 attended the final study visit (D180). One 
participant withdrew secondary to insomnia/vivid dreams (resolved by switching to 
tenofovir/emtricitabine/raltegravir) and the other withdrew for job relocation; both were 
included in D28 PK and PD analyses. Subject and control characteristics are summarised in 
table 2.  
 
 
Dolutegravir plasma pharmacokinetics 
Figure 1 demonstrates GM DTG concentration-time curves for the observed and control 
populations. Steady-state PK parameters are summarised in table 3.  
There were no differences in DTG AUC0-24, C24 or t1/2 between the two populations. However, 
Cmax (approximately two hours post-dose in both groups) was significantly higher in 
subjects≥60 years old (GM 4246 versus 3402 ng/mL, p=0.005).  
Sleep questionnaire results at baseline and follow up 
Detailed response rates and median (IQR) scores per questionnaire, domain and time-point 
are in the supplementary file, table A and figure B.  
 Overall sleep impairment: Pittsburgh Sleep Quality Index (PSQI) [28]  
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Median global PSQI score was higher at D28 versus baseline (5.0 versus 6.0, p=0.02 adjusted 
for multiple testing) but at no other time-points. No domain achieved statistical significance 
individually.  
Internal consistency was acceptable for the global score (α=0.72). Corrected component-total 
correlations ranged from 0.19 (daytime dysfunction) to 0.66 (quality). 
 Insomnia: Insomnia Severity Index (ISI) [29]  
Median (IQR) global ISI scores remained stable (range 5-6.5); four individuals developed 
moderate insomnia over time (ISI 14-21; not significant) and one subject’s severe insomnia 
(ISI>21) improved whilst another’s developed by D28 leading to discontinuation (described 
above).  
 Daytime sleepiness: Epworth Sleepiness Scale (ESS) [30] 
At baseline, 29% individuals were considered ‘sleepy’ (ESS>10) compared with 24% at 
D180 (not significant). 
 Daytime function: Functional Outcomes of Sleep Questionnaire (FOSQ) [31]  
Median (IQR) global FOSQ remained stable from baseline to day D180 (range 18.01-
18.81/20) with a generally good level of daytime function across the cohort. 
 Fatigue severity: Fatigue Severity Scale (FSS) [32] 
At baseline, four/39 (10%) individuals reported having fatigue; this was 20% on D180 (not 
significant). 
 Risks for possessing a sleep disorder: Sleep Disorder Questionnaire (SDQ) [33] 
No participants met the diagnostic criteria at baseline for any of the four sleep disorders tested 
and no significant change in scores was observed over time. 
 Correlation between sleep measures 
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There was a significant correlation between all sleep measures evaluated by more than one 
questionnaire across all scores at baseline (.37<r<.83; p<.05).  
 Sleep scores by efavirenz status 
Seventeen/40 (43%) subjects switched from an efavirenz-based combination. At baseline, 
some measurements appeared worse in individuals who did not switch from efavirenz. No 
significant difference was observed between groups in overall score changes at each time-
point compared to baseline for all questionnaires except ISI, which improved over 180 days 
in participants without efavirenz in their previous regimen and worsened in those with 
(p=0.02); however this did not remain after adjustment for multiple comparisons (p>0.05) 
(supplementary file, table C). 
 Relationship between sleep scores and PK parameters 
There was no correlation between DTG PK parameters and D180 sleep scores or intra-subject 
change in global scores over 180 days (delta test scores) (figure 2; supplementary file, tables 
D and E). To rule out an effect dependent on a drug level threshold, the Mann-Whitney test 
was used to compare delta test scores in subjects with Cmax above the upper quartile (Q4) to 
those below (Q1-3). There were no differences (0.62<p-value<1.0); nor with 95
th
 centile Cmax 
used as threshold (0.13<p-value<0.73).  Similarly, there was no difference in Cmax between 
D180 test score or delta test score low and high quartile groups for all sleep questionnaires 
((0.31≤p-value≤0.66 and 0.63<p-value<1.0). 
Changes in cognitive scores (table 4) 
Between baseline and D180, no change in global cognitive composite scores and individual 
domain scores was observed over time except GML (executive function) where a significant 
improvement from baseline to D180 was seen (median change (IQR) 0.32 (0-0.74), 
unadjusted p=0.002). 
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There was no correlation between C24 and AUC0-24 and D180 cognitive function or delta 
cognitive scores (individual domains and global composite scores; p=0.07). Unexpectedly, 
higher Cmax was associated with improvements in global cognitive function (r=0.39, p=0.02; 
figure 2). The improvement in median (IQR) delta score was higher in those with a 
Cmax>upper 95%CI than in those below (p=0.0195).  
Clinical safety and efficacy 
Two/43 (4.6%) participants discontinued the study secondary to AEs (described above). In 
the remaining subjects, there were no virological failures or grade 3 or 4 toxicity following 
treatment initiation. The studied FDC was well tolerated. 
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DISCUSSION 
We characterized the steady-state PK of DTG 50 mg OD in an aging HIV population, mostly 
over 65 years, the age associated with potential changes in drug PK [24]. Compared to the 
younger control group, Cmax was significantly higher (25%) in those ≥60, indicating increased 
DTG absorption. Whilst the net effect of age-related physiological intestinal changes (e.g. 
reduction in pH, gastrointestinal motility etc.) on the absorption of most drugs is thought to be 
minimal [3], our findings could be explained by age-related alterations in expression of active 
DTG efflux transporters, such P-gP (P-glycoprotein) and BCRP (breast cancer resistance 
protein), across epithelial cells in the gastrointestinal tract [3, 24, 36]; however further 
research is required.
 
There were no differences in DTG C24, AUC0-24 or t1/2 between the two 
groups, supporting a lack of age-associated effect on the main DTG metabolic pathway 
(UGT1A1).  
 
To address the call for prospective PD data [20, 37], we also describe the first post-marketing 
analysis of sleep and cognition-related PD changes, over 180 days following a switch to 
ABC/3TC/DTG. DTG-related NP-AEs (including insomnia) are an emerging concern [14-18] 
and older age has been described as an independent risk factor [13, 16, 19]. In our study, two 
participants discontinued DTG because of NP-AEs (4.6%), which is consistent with published 
cohorts (1.7-8%). However, when investigating sleep quality and Cogstate status in those who 
continued the drug, we only observed a small increase in PSQI scores at D28, which resolved 
by D90, and a non-significant trend towards an increase in FSS score. Other scores remained 
stable or improved following the introduction of DTG. Whilst the one subject who withdrew 
secondary to NP-AEs had elevated levels of DTG, we did not find any association between 
DTG PK parameters and changes in sleep scores in the remaining subjects over time, which is 
in keeping with observations from Riva [38] and Hoffman [39].  There were also no changes 
in sleep scores in subjects with very high drug concentrations in whom, surprisingly, 
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cognition improved significantly. These interesting findings suggest that the mechanisms of 
DTG-related neurotoxicity are likely to be more complex than a simple linear or threshold-
defined PK relationship and may relate to a combination of factors, including 
pharmacogenetic, immune and/or functional predispositions.  
Of interest, Yagura et al found that DTG C24h (≥1.06 μg/mL) correlated with CNS side effects 
in younger Japanese PLWH. No significant difference in DTG concentration was, however, 
observed with individual symptoms or insomnia. The researchers subsequently reported a 
weak association with UGT1A1*6 and UGT1A1*28 alleles [40]. 
 
Capetti et al. found DTG-related sleep disorders resolved in some patients switching to 
morning dosing (0.9% versus 3.5%) [19]. In our study, subjects were dosed in the morning to 
allow for steady state PK measurements; this could partially explain the absence of new sleep 
disturbances, although others researchers report unchanged rates with morning dosing [20, 
40]. Our subject population was a group of only mildly sleep-disturbed individuals from 
baseline, which may also partially explain the lack of positive findings in those who 
completed the study. Overall, whilst sleep impairment rates (PSQI>5) at baseline, matched 
that historically reported in the HIV literature (44-51%), scores were only just in the lower 
range of abnormal (≤7). Additionally, the prevalence of subjects with moderate insomnia 
(ISI) in our cohort (7-21%) is below that previously reported in PLWH [21]. 
 
Controlling for a switch from efavirenz did not change the lack of positive results, likely due 
to the fact that efavirenz subjects in our study were those who do not experience sleep 
disturbances on it. 
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There are limitations to our study. Our subjects were predominantly male, thereby not fully 
representative of real life cohorts. DTG NP-AEs are thought to be higher in women, but this 
is an independent risk factor.  Importantly, our study was not powered to detect changes in 
sleep quality but for the ability to detect PK differences between younger and older PLWH, 
PD results should therefore be interpreted with caution (although our numbers mirrored 
previous HIV sleep studies [21] and consistency across sleep tools (measuring the same 
effect) suggest that results are accurate). Furthermore, the use of self-reported questionnaires 
may compromise intra- and inter-subject consistency and lead to recall bias. The effect of 
suggestion may also introduce bias as was proposed by the authors of the SINGLE trial 
(efavirenz versus DTG) [9] to explain higher rates of DTG-related sleep disturbances. 
Although validated in the general population, our sleep questionnaires are not validated in 
aging PLWH. However, a good correlation between direction changes, reflects good inter-
questionnaire reliability. Finally, the use of historical controls is a limitation, which should be 
addressed in future studies with a larger and active control arm. 
The strengths of our study lie in its prospective and controlled design, investigating a special 
population growing in size and in need of data to tailor HIV treatment appropriately. 
Additionally, we are the first group to characterise detailed sleep and cognitive data in PLWH 
following Triumeq® introduction and to explore the DTG PK/PD relationship in aging 
PLWH. The use of multiple questionnaires allowed a more comprehensive evaluation of sleep 
and its effects than previously reported. 
 
In conclusion, we showed a significantly higher DTG Cmax in PLWH≥60 versus younger 
subjects. The discontinuation rate was similar to previous real-life reports but the Cmax 
increase was not associated with sleep or cognitive decline over six months. This data informs 
physicians and patients on the safety and tolerability of DTG in older patients, particularly 
following the early period where careful monitoring remains recommended [11]. 
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Table 1: summary of content, process and scoring of sleep questionnaires and cognitive 
testing  
 
Questionnaire Process Main Domains Recall 
period 
 
Number 
of 
questions 
Time to 
complete 
(minutes) 
Scores 
PSQI Self- Reported 
0-3 Likert 
scale 
Sleep Quality, 
sleep 
Disturbance and 
sleep habits 
1 
month 
19 5-10 Score of 5 or more 
indicates poor 
sleep quality 
 
Global score 
calculated by 
summing subscale 
scores (not 
calculated for 
individuals with 
missing results) 
ESS Self- Reported  
0-3 Likert 
scale 
Level of 
sleepiness/ 
propensity of 
falling asleep 
N/A 8 < 5 ≥11 indicates 
excessive daytime 
sleepiness 
FOSQ Self- Reported 
0-4 Likert 
scale 
Functional 
impairment in 
activities of 
daily living 
resulting from 
sleepiness  
N/A 30 15 5 domains: for 
each domain, 
lower scores 
indicate more 
acute issues. Each 
domain score 
calculated by 
averaging 
answered domain 
questions. 
 
Global score 
calculated by 
averaging the 
subscale scores & 
multiplying by 5 
(allows for 
missing subscale 
scores) 
ISS Self- Reported 
0-4 Likert 
scale 
Nature, severity 
and impact of 
insomnia 
2 weeks 7 <5 0-7 no insomnia 
8- 14 subthreshold 
insomnia 
15-21 moderate 
insomnia 
22-28 severe 
insomnia 
FSS Self- Reported 
1-7 Likert 
scale 
Effect of fatigue 
on motivation, 
exercise, 
1 week 9 <5  >5 indicates 
abnormal fatigue 
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physical, social 
and family 
functioning 
SDQ Self- Reported 
1-5 Likert 
scale 
Sleep quality 
Sleep 
disturbance 
Daytime 
function 
Medication 
Medical family 
history 
6 
months 
175 30 4 sleep disorders 
categories: Sleep 
Apnoea 
Syndrome, 
Narcolepsy, 
Periodic Limb 
Movements 
Disorders and 
Psychiatric sleep 
disorders. 
Cogstate 
neurocognitive 
test 
Computerised 
battery 
Detection 
Identification 
Set Shifting 
Groton Maze 
Learning 
Groton Maze 
Recall 
One Card 
Learning 
One Back 
Memory 
Two Back 
Memory 
N/A 8 tasks  Score provided for 
each of 8 domains 
using optimal 
outcome measure 
(as defined by 
Cogstate 
guidelines). 
Composite score 
for change from 
baseline calculated 
by averaging 
standardised 
change scores 
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Table 2: Demographic and clinical characteristics of study participants and controls 
 
 Variable Study subject in 
PK analysis 
(n=40) 
Controls 
(n=16) 
Age  Median (range) in years 66 (60-79) 36 (22-50) 
Ethnicity (n) White British/Irish/Other 33 11 
 African Heritage 3 3 
 Hispanic 2 0 
 Asiatic 2 0 
 American Indian/Alaskan Native 0 1 
Gender (n) Male 39 15 
 Female 1 1 
Pre-switch regimen 
Backbone (n) Abacavir/Lamivudine (ABC/3TC) 16 N/A 
 Tenofovir disoproxil fumarate/ 
Emtricitabine(TDF/FTC) 
20 N/A 
3
rd
 Agent (n) Boosted Protease Inhibitor (PI) (of which 
monotherapy and dual therapy with RAL) 
9 
(2 and 1) 
N/A 
 NNRTI (of which Efavirenz) 24 (17) N/A 
 Raltegravir (of which dual therapy with PI) 6 N/A 
 Zidovudine  (AZT) 1 N/A 
Salvage Therapy (n) FTC, Maraviroc, Darunavir, Ritonavir 1 N/A 
 NNRTI: Non Nucleotide Reverse Transcriptase Inhibitor; RAL: Raltegravir; N/A: Not Applicable 
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  Table 3: Dolutegravir steady-state PK parameters for the observed and control groups, measured over 24 hours 
 
Note: The PK parameters for the participant who withdrew secondary to NP-AEs after day 28 were: Cmax 5300 ng/mL, C24 2013 ng/mL, AUC 77942 hr*ng/mL and t1/2 19.8 hrs; 
all >95
th
 percentile for the study group.  
 
 
Observed group (n=40) Control group (n=16) P value (Mann-Whitney U) 
C
max
 
(ng/ml) 
C
min
 
(ng/ml) 
AUC
0-24
 
(ng.h/ml) 
t1/2 (hrs) 
C
max
 
(ng/ml) 
C
min
 
(ng/ml) 
AUC
0-24
 
(ng.h/ml) 
t1/2 (hrs) 
C
max
 
(ng/ml) 
C
min
 
(ng/ml) 
AUC
0-24
 
(ng.h/ml) 
t1/2 (hrs) 
Geomean 4246 1052 51799 12.84 3402 942 48068 14.35 0.00496 0.7718 0.5619 .7065 
Low 95% 4018 999 49405 12.05 3008 799 42350 11.16 - - - - 
Up 95% 4767 1351 59020 14.93 4030 1461 59898 21.44 - - - - 
CV % 27 48 29 34 29 58 34 62 - - - - 
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Table 4. Change in neurocognitive scores (Effect size) 
     
Cogstate domain Cognitive function 
Standardised change score  
(Day 180-baseline) 
n Median (IQR) p-value 
Detection task (DET) Psychomotor function 37 0.02 (-0.16,0.13) 0.743 
Identification task (IDN) Attention 37 -0.04 (-0.47,0.58) 0.602 
Set Shifting (SETS) Executive function 37 0.05 (-0.32,0.75) 0.471 
Groton Maze Learning (GML) Executive function 34 0.32 (0.00,0.74) 0.002** 
Groton Maze Recall (GMR) Delayed recall 35 0.27 (-0.82,1.37) 0.176 
One Card Learning (OCL) Learning 36 0.06 (-0.69,1.00) 0.592 
One Back Memory (ONB) Working memory - simple 37 0.24 (-0.90,0.77) 0.908 
Two Back Memory (TWOB) Working memory - complex 37 0.00 (-0.97,0.84) 0.982 
Composite score   37 0.16 (-0.23,0.37) 0.187 
    
 Cmax <95
th centile  (n = 25) Cmax >95
th centile (n=12) p-value 
Median Cogstate Delta score 
(IQR) 
0.08 (0.30-0.20) 0.41 (0.12-0.64) 0.0195* 
    Note: for difference scores, score sign reversed for all outcome measures where increasing values indicate performance decline. Thus, for 
all measures, negative values indicate performance decline and positive values indicate performance improvement. Difference scores 
standardised according to within-subject standard deviation (WSD). Composite score for each subject calculated by averaging 
standardised change scores across all domains. 
P-values are exact derived from Wilcoxon matched-pairs sign-rank test (not adjusted for multiple comparisons) 
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Figure 1. 
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Figure 2. 
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